On August 27, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported that it participated in the Virtual Investor "Why Now" on-demand conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the webcast, AIM Chief Executive Officer Thomas Equels presented the Company’s investment thesis, highlighting why he believes now is a pivotal time for AIM. The presentation discusses the Company’s progress advancing Ampligen through the Phase 2 DURIPANC clinical trial in metastatic pancreatic cancer, including successful completion of enrollment ahead of schedule, Ampligen dosing of the final patient and the anticipated transition into primary endpoint evaluation in the fourth quarter of 2026, with topline results expected in the first quarter of 2027.

The video webcast is now accessible for on-demand viewing here.

JTC Team and Virtual Investor Co. are paid consultants to AIM ImmunoTech Inc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of AIM ImmunoTech Inc. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company’s website and the SEC website for the latest information and filings on the Company.

(Press release, AIM ImmunoTech, AUG 27, 2026, View Source [SID1234670377])